<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170208</url>
  </required_header>
  <id_info>
    <org_study_id>03985-10-A</org_study_id>
    <secondary_id>R41DK085974</secondary_id>
    <nct_id>NCT01170208</nct_id>
  </id_info>
  <brief_title>Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes</brief_title>
  <official_title>Open-Label, Uncontrolled, Single-Arm, Single-Center, 16-Week Study Assessing Efficacy and Safety of Frequently Modified Insulin Therapy Using Dosage Recommending Device Software in 3-Groups of Subjects With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hygieia, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Diabetes Center at Park Nicollet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effectiveness and safety of the computer
      software program in providing insulin dosage recommendations. Participation in the study for
      60 research subjects will last for 16-weeks and includes 3-4 clinic visits and a series of
      weekly telephone calls from the study team (minimum of 12 calls). Participants will be
      provided with weekly Study Log Sheets to record their daily blood glucose readings, insulin
      doses, grams of carbohydrate eaten at each meal (if they have type-1 diabetes) and any
      changes in their health (e.g., hypoglycemic episodes, illnesses). Participants will fax or
      drop off a copy of the Study Log Sheet. This information will be entered by the IDC study
      team into the computer software program. The IDC study team will review the information from
      the software and, based on the IDC's study team approval, any insulin dose changes will be
      communicated back to the patient by phone or fax.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hygieia, Inc. is developing a device intended for use by insulin-requiring patients with
      diabetes. It will be a pocket-sized, hand-held device, combining a glucose meter with
      software that analyzes blood glucose levels recorded in the device's memory, and periodically
      recommends modifications in insulin dosage. The already developed software algorithms are
      based on the way an endocrinologist evaluates and frequently adjusts insulin dosage in a
      patient with diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Mean Blood Glucose</measure>
    <time_frame>Twelve week period from week 4 to week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Evaluation of ―Over-ride‖ to Determine if the Reason for ―Over-ride‖ Will Affect a Change in the Algorithm.</measure>
    <time_frame>January 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HbA1c.</measure>
    <time_frame>January 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Fructosamine.</measure>
    <time_frame>January 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe or Serious Hypoglycemia.</measure>
    <time_frame>January 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Diabetes</condition>
  <condition>Insulin</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type 2 diabetes treated with basal-bolustherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type 2 diabetes treated with biphasic insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>insulin dose software</intervention_name>
    <description>The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <other_name>blood glucose meter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GROUP I

          -  Have been clinically diagnosed with type-1 diabetes for at least 1-year

          -  Have an HgbA1c of 7.4% or higher

          -  Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart,
             Apidra® Glulisine) before each meal and only one injection of long-acting insulin
             analog Lantus® (Glargine), per day. Subjects must typically eat 3 meals per day. The
             total daily combined dose of the long-acting and short-acting insulin analogs must be
             25 units or more. Patient must have been using the same insulin regimen for the
             previous 3-months

          -  Is currently using an insulin/carbohydrate ratio to decide how much short-acting
             insulin to take before meals and must be able to use the gram versus choice method of
             carbohydrate counting.

          -  GROUP II

          -  Have been clinically diagnosed with type-2 diabetes for at least 1-year

          -  Have an HgbA1c of 7.4% or higher

          -  Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart,
             Apidra® Glulisine) before each meal and only one injection of long-acting insulin
             analog Lantus® (Glargine) per day and. Subjects must typically eat 3 meals per day.
             The total daily combined dose of the long-acting and short-acting insulin analogs must
             be 25 units or more. Patient must have been using the same insulin regimen for the
             previous 3-months

          -  May be using other diabetes agent(s) at a stable dose for the last 3-months.

          -  GROUP III

          -  Have been clinically diagnosed with type-2 diabetes for at least 1-year

          -  Have an HgbA1c of 7.8% or higher

          -  Take twice daily biphasic Insulin (e.g. HumaLog® Mix 75/25, NovoLog® Mix 70/30) or
             premixed insulin (i.e. Humulin® 70/30, Novolin® 70/30, NPH/Regular insulin 70/30) with
             a total daily insulin dose of 25 units and have been using the same insulin regimen
             for the past 3-months

          -  May be using other diabetes agent(s) at a stable dose for the last 3-months.

        Exclusion Criteria:

          -  Have a history of greater than 2 episodes of severe hypoglycemia in the past year, or
             have hypoglycemic unawareness when glucose levels are less than or equal to 50 mg/dl

          -  Have a significant physical, psychological, or cognitive impairment that would
             prohibit adherence to the protocol

          -  Have any severe cardiovascular disease including a history of congestive heart failure
             (New York Heart Association [NYHA] 3 or 4), unstable angina, myocardial infarction or
             stroke that occurred within the 6-months preceding enrollment

          -  Have known active anemia with a hemotocrit less than 25% in women or 30% in men

          -  Have known history of renal disease (e.g., serum creatinine level &gt;2.0 mg/dl or eGFR &lt;
             30 ml/min)

          -  Have active cancer or cancer in the past 2-years (except non-melanoma skin cancer

          -  Have history of significant liver disease including cirrhosis or elevated liver
             enzymes (e.g., AST and ALT greater than 3 times the upper limit of normal values)

          -  Have a body mass index (BMI) &gt; 45 kg/m2; and/or

          -  Are pregnant, plan to become pregnant during the study period, or are breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Bergenstal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eran Bashan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hygieia, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22568777</url>
    <description>Publication</description>
  </link>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005 Jul;28(7):1568-73.</citation>
    <PMID>15983302</PMID>
  </reference>
  <reference>
    <citation>Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008 Jul;31(7):1305-10. doi: 10.2337/dc07-2137. Epub 2008 Mar 25.</citation>
    <PMID>18364392</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <results_first_submitted>September 5, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2014</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin</keyword>
  <keyword>dosage software</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>July 2010 to October 2010. Location: Medical Clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I</title>
          <description>Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting</description>
        </group>
        <group group_id="P2">
          <title>Group II</title>
          <description>Type 2 diabetes treated with basalbolus therapy</description>
        </group>
        <group group_id="P3">
          <title>Group III</title>
          <description>Type 2 diabetes treated with biphasic insulin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I</title>
          <description>Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting</description>
        </group>
        <group group_id="B2">
          <title>Group II</title>
          <description>Type 2 diabetes treated with basalbolus therapy</description>
        </group>
        <group group_id="B3">
          <title>Group III</title>
          <description>Type 2 diabetes treated with biphasic insulin.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="12"/>
                    <measurement group_id="B2" value="60" spread="7"/>
                    <measurement group_id="B3" value="55" spread="7"/>
                    <measurement group_id="B4" value="52" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly Mean Blood Glucose</title>
          <description>Week 4 baseline weekly mean blood glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176.9" spread="28.3"/>
                    <measurement group_id="B2" value="164.9" spread="37.6"/>
                    <measurement group_id="B3" value="190.8" spread="47.0"/>
                    <measurement group_id="B4" value="172.4" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weekly Mean Blood Glucose</title>
        <time_frame>Twelve week period from week 4 to week 16</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Type 1 diabetes treated with basal-bolus insulin the</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Type 2 diabetes treated with basal bolus therapy</description>
          </group>
          <group group_id="O3">
            <title>Group III</title>
            <description>Type 2 diabetes treated with biphasic insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Blood Glucose</title>
          <population>Per Protocol</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.2" spread="26.9"/>
                    <measurement group_id="O2" value="156.8" spread="40.5"/>
                    <measurement group_id="O3" value="161.3" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Evaluation of ―Over-ride‖ to Determine if the Reason for ―Over-ride‖ Will Affect a Change in the Algorithm.</title>
        <time_frame>January 2011</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in HbA1c.</title>
        <time_frame>January 2011</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Fructosamine.</title>
        <time_frame>January 2011</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe or Serious Hypoglycemia.</title>
        <time_frame>January 2011</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group I</title>
          <description>Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting</description>
        </group>
        <group group_id="E2">
          <title>Group II</title>
          <description>Type 2 diabetes treated with basalbolus therapy</description>
        </group>
        <group group_id="E3">
          <title>Group III</title>
          <description>Type 2 diabetes treated with biphasic insulin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was limited by lack of a control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard Bergenstal</name_or_title>
      <organization>International Diabetes Center</organization>
      <phone>952-993-3796</phone>
      <email>richard.bergenstal@parknicollet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

